We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MQQQ:NASDAQTradr 2X Long Innovation 100 Monthly ETF Analysis

Data as of 2026-08-10 - not real-time

$232.99

Latest Price

8/10Risk

Risk Level: High

Executive Summary

At $232.99, Tradr 2X Long Innovation 100 Monthly ETF shows no decisive moving-average alignment, leaving the trend neutral. RSI sits at 56.1, which reads as neutral, and MACD momentum is bullish. Recent trading has carved out support near $194.04 and resistance around $236.23.
The 0.95% expense ratio is middling for its category, and the fund manages $200.4M in assets.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 52.4%, a beta of 2.84 and a maximum drawdown of 26.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Trading above the 200-day average of 198.01
  • MACD momentum is positive
  • 30-day volatility of 52.4%

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Trading above the 200-day average of 198.01
  • 30-day volatility of 52.4%
  • MACD momentum is positive

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • 30-day volatility of 52.4%
  • Beta of 2.84 versus the benchmark
  • Maximum drawdown of 26.7%

Key Metrics & Analysis

Fund Metrics

Expense Ratio0.95%
AUM$200.4M
Inception Date2024-08-30
Avg Daily Volume27,220
Premium/Discount0.00%
Tracking Error0.00%

Technical Analysis

TrendNeutral
RSI56.1
Support$194.04
Resistance$236.23
MA 20$219.88
MA 50$230.35
MA 200$198.01
MACDBullish
VolumeDecreasing
Fear & Greed Index93.86

Risk Assessment

Beta2.84
Volatility52.42%
Sector RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.